Angiopoietin concentrations in diabetic retinopathy

J. I. Patel, P. G. Hykin, Z. J. Gregor, M. Boulton, I. A. Cree

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little Information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy. Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy. Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection. Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.

Original languageEnglish (US)
Pages (from-to)480-483
Number of pages4
JournalBritish Journal of Ophthalmology
Volume89
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Angiopoietins
Angiopoietin-2
Diabetic Retinopathy
Angiopoietin-1
Macular Edema
Retinal Perforations
Vascular Endothelial Growth Factor A
Vitrectomy
Retinal Vessels
Temazepam
Capillary Permeability
Luminescence
Immunoassay
Limit of Detection
Permeability

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Patel, J. I., Hykin, P. G., Gregor, Z. J., Boulton, M., & Cree, I. A. (2005). Angiopoietin concentrations in diabetic retinopathy. British Journal of Ophthalmology, 89(4), 480-483. https://doi.org/10.1136/bjo.2004.049940

Angiopoietin concentrations in diabetic retinopathy. / Patel, J. I.; Hykin, P. G.; Gregor, Z. J.; Boulton, M.; Cree, I. A.

In: British Journal of Ophthalmology, Vol. 89, No. 4, 04.2005, p. 480-483.

Research output: Contribution to journalArticle

Patel, JI, Hykin, PG, Gregor, ZJ, Boulton, M & Cree, IA 2005, 'Angiopoietin concentrations in diabetic retinopathy', British Journal of Ophthalmology, vol. 89, no. 4, pp. 480-483. https://doi.org/10.1136/bjo.2004.049940
Patel, J. I. ; Hykin, P. G. ; Gregor, Z. J. ; Boulton, M. ; Cree, I. A. / Angiopoietin concentrations in diabetic retinopathy. In: British Journal of Ophthalmology. 2005 ; Vol. 89, No. 4. pp. 480-483.
@article{3c2cfbe57ccd494bbde8ff78757a30f7,
title = "Angiopoietin concentrations in diabetic retinopathy",
abstract = "Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little Information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy. Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy. Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection. Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.",
author = "Patel, {J. I.} and Hykin, {P. G.} and Gregor, {Z. J.} and M. Boulton and Cree, {I. A.}",
year = "2005",
month = "4",
doi = "10.1136/bjo.2004.049940",
language = "English (US)",
volume = "89",
pages = "480--483",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Angiopoietin concentrations in diabetic retinopathy

AU - Patel, J. I.

AU - Hykin, P. G.

AU - Gregor, Z. J.

AU - Boulton, M.

AU - Cree, I. A.

PY - 2005/4

Y1 - 2005/4

N2 - Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little Information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy. Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy. Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection. Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.

AB - Background/aim: Angiopoietin 1 and 2 interact with vascular endothelial growth factor (VEGF) to promote angiogenesis in animal and in vitro models. Although VEGF concentrations are elevated, there is little Information regarding angiopoietin concentration in the vitreous of patients with diabetic retinopathy. Methods: Angiopoietin concentrations were measured by luminescence immunoassay in vitreous samples from 17 patients with non-proliferative diabetic retinopathy (NPDR) and clinically significant diabetic macular oedema (CSMO), 10 patients with proliferative diabetic retinopathy (PDR), and five patients with macular hole (controls) obtained at pars plana vitrectomy. Results: Angiopoietin 1 concentrations were low in patients with macular hole (median 17 pg/ml) while in NPDR with CSMO they were 2002 pg/ml (range 289-5820 pg/ml) and in PDR 186 pg/ml (range 26-2292 pg/ml). Angiopoietin 2 concentrations in NPDR with CSMO were a median of 4000 pg/ml (range 1341-14329 pg/ml). For both macular hole and PDR patients angiopoietin 2 was below the limit of detection. Conclusions: Angiopoietin 2 concentration was twice that of angiopoietin 1 in NPDR with CSMO. Angiopoietin 2 is the natural antagonist of angiopoietin 1 which is thought to act as an anti-permeability agent. The predominance of angiopoietin 2 may allow VEGF induced retinal vascular permeability in patients with CSMO. The relatively low concentration of both angiopoietin 1 and 2 in patients with proliferative diabetic retinopathy may reflect the established nature of the neovascularisation in cases proceeding to vitrectomy.

UR - http://www.scopus.com/inward/record.url?scp=16244402264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16244402264&partnerID=8YFLogxK

U2 - 10.1136/bjo.2004.049940

DO - 10.1136/bjo.2004.049940

M3 - Article

VL - 89

SP - 480

EP - 483

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -